宁心宝胶囊治疗心律失常的疗效及安全性系统评价及Meta分析  

Systematic review and Meta-analysis of efficacy and safety of Ningxinbao Capsules in treatment of arrhythmia

作　　者：贾君迪 李玉峰[1] 肖珉[1] 姜旭[1] 修晟尧 王洁[1] JIA Jun-di;LI Yu-feng;XIAO Min;JIANG Xu;XIU Sheng-yao;WANG Jie(Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China)

机构地区：[1]北京中医药大学东直门医院,北京100700

出　　处：《中国中药杂志》2021年第5期1260-1267,共8页China Journal of Chinese Materia Medica

基　　金：第四批全国中医临床优秀人才研修项目(T20194832001)。

摘　　要：对公开发表的应用宁心宝胶囊治疗心律失常的临床疗效及安全性进行系统评价。计算机检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文科技期刊全文数据库(VIP)、中国生物医学文献数据库(SinoMed)、PubMed、Web of Science、Cochrane Library、EMbase以及手工检索相关资料,全面收集宁心宝胶囊治疗心律失常的随机对照试验(RCT)及半随机对照试验。所有数据库检索时限均为建库至2020年4月7日。随后根据研究的纳入和排除标准,对文献进行筛选,质量评价及提取有效数据,采用RevMan 5.3软件进行Meta分析。共纳入13篇文献,包括1379例患者,试验组干预措施为宁心宝胶囊联合抗心律失常西药治疗,对照组干预措施为常规抗心律失常西药治疗。Meta分析结果显示,宁心宝胶囊联合抗心律失常西药在提高心律失常患者临床疗效,改善动态心电图,改善缓慢型心律失常患者平均心率上优于对照组,差异有统计学意义。与对照组相比,宁心宝胶囊的不良反应较少,可能具有改善抗心律失常西药的毒副作用。该研究发现宁心宝胶囊对于心律失常患者具有一定的作用,且相对安全。但因纳入研究的质量有限,还需开展高质量的临床试验加以证实。To systematically evaluate the efficacy and safety of Ningxinbao Capsules in treatment of arrhythmia by Meta-analysis.Randomized controlled trial(RCT)or quasi-randomized control trial(Quasi-RCT)on Ningxinbao Capsules treating arrhythmia were obtained by computer-based retrieval in CNKI,Wanfang,VIP,SinoMed,PubMed,Web of Science,Cochrane Library and EMbase as well as manual retrieval,with time limit from database establishment to April 7,2020.According to the inclusion and exclusion criteria of trials,all RCTs were screened and evaluated.Then the effective data were collected and RevMan 5.3 Meta-analysis software was used for analysis.Thirteen trials were included,involving 1379 patients in total.Ningxinbao Capsules combined with anti-arrhythmia Western medicine were adopted as the intervention,and the patients in control group were treated with the anti-arrhythmia Western medicine alone.Meta-analysis results showed that as compared to control group,Ningxinbao Capsules combined with anti-arrhythmia Western medicine group was superior in clinical efficacy,dynamic electrocardiogram and average heart rate in patients with bradycardia,with indicated statistically significant differences.Ningxinbao Capsules had fewer adverse reactions and could relieve the toxic and side effects of anti-arrhythmia medicine possibly.The study showed that Ningxinbao Capsules played a role in treatment of arrhythmia and was relatively safe.However,due to the limited quality of the included studies,high-quality clinical trials are needed to verify the conclusions.

关 键 词：宁心宝胶囊 心律失常 系统评价 META分析 

分 类 号：R259[医药卫生—中西医结合]